Emerging drug delivery in the treatment of hyperpituitarism and hypopituitarism

Arora, V; Kabra, A; Puri, R; Vyas, G; Dua, K; Dureja, H

Emerging drug delivery in the treatment of hyperpituitarism and hypopituitarism

Arora, V Kabra, A Puri, R Vyas, G Dua, K

Dureja, H

Permalink

Publisher:: Elsevier
Publication Type:: Chapter
Citation:: Drug Delivery Systems for Metabolic Disorders, 2022, pp. 249-257
Issue Date:: 2022-01-01

Closed Access

	Filename	Description	Size
	3-s2.0-B9780323996167000049-main.pdf	Published version	666.25 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Arora, V
dc.contributor.author	Kabra, A
dc.contributor.author	Puri, R
dc.contributor.author	Vyas, G
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Dureja, H
dc.date.accessioned	2023-02-25T07:04:28Z
dc.date.available	2023-02-25T07:04:28Z
dc.date.issued	2022-01-01
dc.identifier.citation	Drug Delivery Systems for Metabolic Disorders, 2022, pp. 249-257
dc.identifier.isbn	9780323996334
dc.identifier.uri	http://hdl.handle.net/10453/166428
dc.description.abstract	Hypopituitarism (failure to produce or underproduction of hormones released by the pituitary) and hyperpituitarism (excess production of hormones by the pituitary gland) are chronic endocrine disorders that arise as an outcome of diseases that affect brain tissue, namely metastatic deposits, primary tumors, trauma, surgery, radiotherapy, and vascular accidents. Hypopituitarism is correlated more with excessive incidences of mortality, as compared to hyperpituitarism. The common treatment for the management of hypopituitarism is hormone replacement therapy, but the continuous administration of certain hormones and their synthetic analogs may show substantially unexpected outcomes. Whereas in the case of tumor-associated compression and tissue damage leading to hypopituitarism the conventional approach of radiotherapy may be utilized to lower the tumor size and hence the revival of normal pituitary functions. On the other hand, the treatment of hyperpituitarism varies based upon the disease-causing factor and hormones impacted, which includes the use of competitive receptor antagonists for that specific hormone. For example, in patients with excessive secretion of growth hormone the analogs of somatostatin have been used effectively. Various literature revealed that the brain tissue differs from the other tissues of the body due to its restrictive blood-brain barrier which is the major limitation for designing alternative treatments for the diseased state associated with the pituitary. In such cases, nanotechnological approaches can be a promising alternative, especially during postsurgical treatment. This chapter seeks to provide an overview of research breakthroughs, drug therapy development trends, and delivery system applications in the treatment of hypopituitarism and hyperpituitarism.
dc.language	en
dc.publisher	Elsevier
dc.relation.ispartof	Drug Delivery Systems for Metabolic Disorders
dc.relation.isbasedon	10.1016/B978-0-323-99616-7.00004-9
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	Emerging drug delivery in the treatment of hyperpituitarism and hypopituitarism
dc.type	Chapter
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2023-02-25T07:04:27Z
pubs.publication-status	Published

Abstract:

Hypopituitarism (failure to produce or underproduction of hormones released by the pituitary) and hyperpituitarism (excess production of hormones by the pituitary gland) are chronic endocrine disorders that arise as an outcome of diseases that affect brain tissue, namely metastatic deposits, primary tumors, trauma, surgery, radiotherapy, and vascular accidents. Hypopituitarism is correlated more with excessive incidences of mortality, as compared to hyperpituitarism. The common treatment for the management of hypopituitarism is hormone replacement therapy, but the continuous administration of certain hormones and their synthetic analogs may show substantially unexpected outcomes. Whereas in the case of tumor-associated compression and tissue damage leading to hypopituitarism the conventional approach of radiotherapy may be utilized to lower the tumor size and hence the revival of normal pituitary functions. On the other hand, the treatment of hyperpituitarism varies based upon the disease-causing factor and hormones impacted, which includes the use of competitive receptor antagonists for that specific hormone. For example, in patients with excessive secretion of growth hormone the analogs of somatostatin have been used effectively. Various literature revealed that the brain tissue differs from the other tissues of the body due to its restrictive blood-brain barrier which is the major limitation for designing alternative treatments for the diseased state associated with the pituitary. In such cases, nanotechnological approaches can be a promising alternative, especially during postsurgical treatment. This chapter seeks to provide an overview of research breakthroughs, drug therapy development trends, and delivery system applications in the treatment of hypopituitarism and hyperpituitarism.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166428